Fulcrum therapeutics® reports recent business highlights and fourth quarter and full year 2021 financial results

– clear path forward for phase 3 reach trial with losmapimod in fshd; trial expected to begin in 2q 2022 –
FULC Ratings Summary
FULC Quant Ranking